One Podium and Two Poster Presentations
Will Highlight Pre-Clinical and Clinical Data for Investigational
Treatment NOV03, as well as Data from Company's Unique ARMOR
Surveillance Study
VAUGHAN,
ON, Sept. 27, 2022 /PRNewswire/ -- Bausch +
Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading
global eye health company dedicated to helping people see better to
live better, today announced the presentation of one podium
and two poster presentations at the World Cornea Congress VIII
meeting, which will take place in Chicago from Sept.
28-29, 2022.
The podium presentation will feature findings from the pivotal
Phase 3 trials of the investigational treatment NOV03
(perfluorohexyloctane), and the poster presentations will include
pre-clinical data of NOV03 and data from Bausch + Lomb's ongoing
Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR)
surveillance study. The ARMOR study is the only ongoing
surveillance study of its kind that evaluates profiles and trends
in antibiotic resistance among common ocular bacterial pathogens
across the United States.
"With the recent FDA acceptance of the New Drug Application for
NOV03, we look forward to attending the World Cornea Congress so we
can share valuable insights from our NOV03 clinical development
program with the ophthalmic community," said Christina Ackermann, president, Ophthalmic
Pharmaceuticals, Bausch + Lomb. "We will also present findings from
our unique ARMOR study, which for more than a decade has helped
guide eye care professionals in selecting the most appropriate
antibiotic treatment options to meet the needs of their
patients."
Following is a complete list of titles and lead authors for each
of the presentations:
Podium Presentation
- "NOV03 for the Treatment of Signs and Symptoms of Dry Eye
Disease Associated with Meibomian Gland Dysfunction: GOBI and
MOJAVE Study Findings." Tauber et al.
Poster Presentations
- "In Vitro Antibiotic Resistance among Bacterial Pathogens
Sourced from the Cornea in ARMOR." Asbell et al.
- "In Vitro Studies of Perfluorohexyloctane, an
Investigational Eye Drop for Dry Eye Disease." Borchman et
al.
About Bausch + Lomb
Bausch + Lomb is dedicated
to protecting and enhancing the gift of sight for millions of
people around the world – from the moment of birth through every
phase of life. Its comprehensive portfolio of more than 400
products includes contact lenses, lens care products, eye care
products, ophthalmic pharmaceuticals, over-the-counter products and
ophthalmic surgical devices and instruments. Founded in 1853,
Bausch + Lomb has a significant global research and development,
manufacturing and commercial footprint with more than 12,000
employees and a presence in nearly 100 countries. Bausch + Lomb is
headquartered in Vaughan, Ontario
with corporate offices in Bridgewater, New Jersey. For more information,
visit www.bausch.com and connect with us
on Twitter, LinkedIn, Facebook
and Instagram.
Forward-looking Statements
This news release may
contain forward-looking statements, which may generally be
identified by the use of the words "anticipates," "hopes,"
"expects," "intends," "plans," "should," "could," "would," "may,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, the risks and uncertainties discussed in Bausch +
Lomb's filings with the U.S. Securities and Exchange Commission and
the Canadian Securities Administrators, which factors are
incorporated herein by reference. They also include, but are not
limited to, risks and uncertainties caused by or relating to the
evolving COVID-19 pandemic, and the fear of that pandemic and its
potential effects, the severity, duration and future impact of
which are highly uncertain and cannot be predicted, and which may
have a material adverse impact on Bausch + Lomb, including but not
limited to its project development timelines, launches and costs
(which may increase). Readers are cautioned not to place undue
reliance on any of these forward-looking statements. These
forward-looking statements speak only as of the date hereof. Bausch
+ Lomb undertakes no obligation to update any of these
forward-looking statements to reflect events or circumstances after
the date of this news release or to reflect actual outcomes, unless
required by law.
All product/brand
names are trademarks of the respective owners.
© 2022 Bausch & Lomb Incorporated or its affiliates.
NOV03.0030.USA.22
|
Investor
Contacts:
|
Media
Contacts:
|
Arthur Shannon
|
Lainie
Keller
|
arthur.shannon@bausch.com
|
lainie.keller@bausch.com
|
|
(908)
927-1198
|
Allison Ryan
|
|
allison.ryan@bausch.com
|
Kristy
Marks
|
(877) 354-3705 (toll
free)
|
kristy.marks@bausch.com
|
(908) 927-0735
|
(908)
927-0683
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bausch--lomb-will-present-scientific-data-and-analyses-during-world-cornea-congress-301633671.html
SOURCE Bausch + Lomb Corporation